The expanded FDA clearance for Collaboration Live (Philips) gives clinicians the option to consult on or diagnose ultrasound images from their mobile devices.
In a promising development for real-time remote collaboration between physicians consulting on ultrasound images, the Food and Drug Administration (FDA) has expanded the 510(k) clearance of Collaboration Live (Philips) to include use of the tele-ultrasound platform on additional mobile devices.
Philips said the expanded FDA clearance will significantly enhance efficiency and flexibility for clinicians as they will no longer be restricted to a personal computer (PC) when consulting with colleagues via Collaboration Live. The secure platform reportedly allows clinicians who are using Collaboration Live on the Philips EPIQ or Affiniti ultrasound systems to share the screen and video stream directly to compatible PCs and mobile devices of fellow clinicians, according to the company.
“Sonographers no longer have to feel they are alone or limited to only acquiring ultrasound images and preparing a report for subsequent clinical review,” noted Gerois Di Marco, the general manager of global ultrasound services and solutions at Philips. “They can now call on the expertise of colleagues during ultrasound examinations to deliver on the spot accurate diagnosis that every patient deserves.”
Another benefit of the tele-ultrasound platform is the ability of the ultrasound user to cede control to the remote clinician, enabling him or her to make measurements, obtain a new image or enhance image quality, according to Philips.
Michael S. Ruma, MD, MPH, who is affiliated with Perinatal Associates of New Mexico, said the technology of Collaboration Live can have an impact in extending quality care to underserved communities.
“We have been able to open a strictly telemedicine office to serve our patients in rural communities because Collaboration Live enables us to carry out a full diagnostic visit remotely,” explained Dr. Ruma, a fellow of the American College of Obstetricians and Gynecologists.
Leading Breast Radiologists Discuss the USPSTF Breast Cancer Screening Recommendations
May 17th 2024In recognition of National Women’s Health Week, Dana Bonaminio, MD, Amy Patel, MD, and Stacy Smith-Foley, MD, shared their thoughts and perspectives on the recently updated breast cancer screening recommendations from the United States Preventive Services Task Force (USPSTF).
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Appealing Prior Authorization Denials: Can it be Effective for Emerging Technologies?
May 14th 2024While radiologists and other providers may be discouraged by insurer denials saying the use of a technological advance is “unproven and investigational,” 82 percent of appeals for prior authorization denials were approved in 2021.
Current Insights and Emerging Roles for Contrast-Enhanced Mammography
May 10th 2024In a recent lecture at the 2024 ARRS Annual Meeting, Jordana Phillips, MD, discussed the role of contrast-enhanced mammography in staging breast cancer, evaluating response to neoadjuvant chemotherapy and recalls from screening.